10,12-DIAZAPROSTAGLANDIN ANALOGUES

F. Cassidy and G. Wootton*

Beecham Pharmaceuticals, Medicinal Research Centre, The Pinnacles, Harlow, Essex, England.

Considerable interest has been shown recently in the synthesis and biological activities of azaprostaglandin analogues.¹⁻⁹ As a continuation of our work in this area,^{3,9} we have developed a versatile, high yielding route (Scheme 1) to 10,12-diazaprostaglandin analogues from readily available starting materials.



Methods for the synthesis of (1), (2) and (3) have been reported elsewhere.³ Reaction of the amino di-ester (3) with methyl isocyanate gave, directly, the 10,12-diazaprostaglandin analogue (5), <u>via</u> thermal cyclisation of the intermediate urea derivative (4). The analogue (5), which was obtained as a colourless gum after column chromatography,¹⁰ was subjected to alkaline hydrolysis to obtain the acid (6). The thermal cyclisation did not occur when <u>tert</u>-butylisocyanate was used in place of methyl isocyanate and the isolated product was the urea (7). However, the required 10,12-diazaprostaglandin analogue (8) was obtained, albeit in low yield, <u>via</u> cyclisation of (7) with potassium <u>tert</u>-butoxide in toluene. The yield of this cyclisation reaction was increased considerably when the diethyl rather than the dimethyl ester was used.



i; (CH₃)₃CNCO, reflux in toluene, 3 hrs.
ii; KOC(CH₃)₃, reflux in toluene, 3 hrs.

The route outlined in Scheme 1 was also used to produce a series of l1-thio-10,12-diazaprostaglandin analogues. For example, reaction of the amino di-ester (3) with methyl isothiocyanate gave the ester (9) as a pale yellow gum after column chromatography.



i; CH₃NCS, reflux in toluene, 3 hrs.

In order to obtain 10-unsubstituted 10,12-diazaprostaglandin analogues, a different approach was necessary. For example, reaction of the amino di-ester (3) with potassium cyanate and dilute hydrochloric acid gave the urea (10) which was thermally cyclised to the 10,12-diazaprostaglandin analogue (11). Subsequent alkaline hydrolysis gave the acid (12).



iii; K₂CO₃, H₂O, CH₃OH, reflux.

The acidic nature of the proton at the 10-position of (11) was utilised in an alternative route to the 10-substituted analogues. Thus, conversion of (11) to its 10-sodium salt, followed by treatment with methyl bromoacetate gave the di-ester (13) as a colourless gum after column chromatography.



i; NaH, DMF, room temperature, 2 hrs. ii; CH₃O₂CCH₂Br, DMF, room temperature, 5 hrs.

The 10,12-diazaprostaglandin analogues were obtained as mixtures of diastereoisomers.

Data for compounds (5) to (13)

Compound (5): Yield 82% from (3). IR: v_{max} , (film), 3450, 1765, 1735, 1705 cm⁻¹. NMR¹¹: τ , (CDCl₃), 7.75 (m, 2H, CH₂CO₂CH₃); 7.25 (s, 1H, OH); 7.07 (s, 3H, NCH₃); 6.7 (brm, 2H, NCH₂); 6.38 (s, 3H, CO₂CH₃); 6.05 ppm (m, 1H, NCH). Mass spectrum: m/e (m*) requires 398.2778; found 398.2757. Compound (6): Yield 86% from (5). IR: v_{max} , (film), 3600 to 2400, 1760, 1700 (broad) cm⁻¹ NMR: τ , (CDCl₃), 7.65 (t, 2H, CH₂CO₂H); 7.0 (s, 3H, NCH₃); 6.6 (brm, 2H, NCH₂); 5.95 (t, 1H, NCH); 3.65 ppm (bs, 2H, CO₂H, OH). Mass spectrum: m/e (m*) requires 384.2622; found 384.2601. Compound (7): Yield 85% from (3). IR: v_{max} , (film), 3350, 1740, 1630 cm⁻¹. NMR: τ ,

(CC1₄), 7.75 (t, 2H, CH₂CO₂CH₃); 7.1 (bs, 1H, OH); 6.8 (m, 2H, NCH₂); 6.4 (s, 3H, CO₂CH₃); 6.35 ppm (s, 3H, CO₂CH₃). Mass spectrum: m/e (m*) requires 472.3512; found 472.3511.

Compound (8): Yield 15% from (7). IR: ν_{max} , (film), 3450, 1760, 1740, 1700 cm⁻¹. NMR: τ , (CCl₂), 7.75 (t, 2H, CH₂CO₂CH₃); 7.1 (s, 1H, OH); 6.8 (brm, 2H, NCH₂); 6.4 (s, 3H, CO₂CH₃); 6.25 ppm (m, 1H, NCH). Mass spectrum: m/e (m*) requires 440.3331; found 440.3258. Compound (9): Yield 88% from (3). IR: v_{max} , (film), 3470, 1740 cm⁻¹. NMR: τ , (CC1₄), 7.85 (t, 2H, CH₂CO₂CH₃); 7.75 (s, 1H, OH); 6.7 (brm, 2H, NCH₂); 6.82 (s, 3H, NCH₃); 6.4 (s, 3H, CO₂CH₂); 5.9 ppm (brm, 1H, NCH). Mass spectrum: m/e (m*) requires 414.2549; found 414.2565. Compound (10): Yield 100% (crude) from (3). IR: v_{max}, (film), 3600 to 2800, 1720, 1660, 1600 cm⁻¹. NMR: τ , (CDCl₃), 7.75 (t, 2H, CH₂CO₂CH₃); 6.8 (brm, 2H, NCH₂); 6.4 (s, 3H, CO₂CH₃); 5.95 ppm (m, 1H, NCH). Compound (11): Quantitative yield from (10). IR: v_{max} , (film), 3450, 3200, 1760, 1710 cm⁻¹. NMR: 7, (CC1₄), 7.75 (t, 2H, CH₂CO₂CH₃); 6.7 (brm, 2H, NCH₂); 6.35 (s, 3H, CO₂CH₃); 5.95 ppm (m, 1H, NCH). Mass spectrum: m/e (m*) requires 384.2622; found 384.2620. Compound (12): Quantitative yield from (11). IR: v_{max}, (film), 3600 to 2500, 3400, 3200, 1760, 1710 cm⁻¹. NMR: τ , (CDC1₃), 7.65 (m, 2H, CH₂CO₂H); 6.4 (brm, 2H, NCH₂); 5.9 (bs, 1H, NCH); 3.2 (bs, 2H, CO₂H, OH); 0.55 ppm (bs, 1H, CONHCO). Mass spectrum: m/e (m*) requires 370.2466; found 370.2473. Compound (13): Yield 98% from (11). IR: v_{max} , (film), 3450, 1760, 1720 (shoulder), 1710 cm⁻¹ NMR: τ , (CC1₄), 7.75 (t, 2H, CH₂CO₂CH₃); 7.15 (d, 1H, OH); 6.8 (brm, 2H, NCH₂); 6.4 (s, 3H, CO₂CH₃); 6.25 (s, 3H, CO₂CH₃); 5.95 (m, 1H, NCH); 5.85 ppm (s, 2H, NCH₂CO₂CH₃). Mass spectrum: m/e (m*-H₂0) requires 438.2726; found 438.2719.

References, Notes and Acknowledgements

- 1. G. Bolliger and J.M. Muchowski, Tetrahedron Letters, 2931 (1975).
- 2. J.W. Bruin, H. deKonig and H.O. Huisman, <u>Tetrahedron Letters</u>, 4599 (1975).
- 3. Belgian Patent BE 835,989 (1976).
- 4. R.M. Scribner, Tetrahedron Letters, 3853 (1976).
- 5. P.A. Zoretic and F. Barcelos, Tetrahedron Letters, 529 (1977).
- R.L. Smith, Ta-jyh Lee, N.P. Gould, E.J. Cragoe Jnr., H.G. Oien and F.A. Kuehl Jnr., J. Med. Chem., <u>20</u>, 1292 (1977).
- 7. R.M. Scribner, Prostaglandins, 13, 677 (1977).
- 8. West German Patent DT 2724948 (1976).
- 9. West German Patent DT 2755771 (1976).
- Column chromatography was carried out on silica gel using chloroform and/or chloroform methanol mixtures as eluants.
- 11. NMR spectra were determined on a Perkin Elmer R12A (60 MHz) instrument using TMS as internal standard.

The authors thank Miss K. Baker for valuable technical assistance.

(Received in UK 6 February 1979)